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Abstract. Epidemiological studies indicate that long‑term 
aspirin usage reduces the incidence of colorectal cancer 
(CRC) and may protect against other non‑CRC associated 
adenocarcinomas, including oesophageal cancer. A number of 
hypotheses have been proposed with respect to the molecular 
action of aspirin and other non‑steroidal anti‑inflammatory 
drugs in cancer development. The mechanism by which aspirin 
exhibits toxicity to CRC has been previously investigated by 
synthesising novel analogues and derivatives of aspirin in an 
effort to identify functionally significant moieties. Herein, an 
early effect of aspirin and aspirin‑like analogues against the 
SW480 CRC cell line was investigated, with a particular focus 
on critical molecules in the epidermal growth factor (EGF) 
pathway. The present authors proposed that aspirin, diaspirin 
and analogues, and diflunisal (a salicylic acid derivative) may 
rapidly perturb EGF and EGF receptor (EGFR) internalisation. 
Upon longer incubations, the diaspirins and thioaspirins may 
inhibit EGFR phosphorylation at Tyr1045 and Tyr1173. It was 
additionally demonstrated, using a qualitative approach, that 
EGF internalisation in the SW480 cell line may be directed 
to endosomes by fumaryldiaspirin using early endosome 
antigen 1 as an early endosomal marker and that EGF 
internalisation may also be perturbed in oesophageal cell 
lines, suggestive of an effect not only restricted to CRC cells. 
Taken together and in light of our previous findings that the 
aspirin‑like analogues can affect cyclin D1 expression and 
nuclear factor‑κB localisation, it was hypothesized that aspirin 
and aspirin analogues significantly and swiftly perturb the 
EGFR axis and that the protective activity of aspirin may 
in part be explained by perturbed EGFR internalisation and 
activation. These findings may also have implications in 
understanding the inhibitory effect of aspirin and salicylates 
on wound healing, given the critical role of EGF in the 
response to tissue trauma.
Introduction
A total of ~600,000 patients annually succumb to colorectal 
cancer (CRC) worldwide (1), with indications that the incidence 
is on the rise, particularly in Asia (2,3) and possibly in the 
younger population in the USA (4). Regular aspirin intake 
significantly reduces the risk of developing CRC and other 
gastrointestinal tract malignancies (5,6), which has caused 
debate regarding regular aspirin use as a chemopreventive 
agent on a population basis (7,8). Aspirin usage following 
a diagnosis of colon cancer also has a positive outcome: 
Longer survival has been reported among patients with 
mutated‑PIK3CA CRC, but not those with wild‑type PIK3CA 
cancer (9).
Despite vigorous investigation, the molecular basis for 
the chemopreventive effect of aspirin remains controversial 
and a large number of molecular targets of aspirin and 
salicylates have been suggested (10). The molecular effects 
on cells and tissues include but are not limited to: Inhibition 
of cyclooxygenase (COX) activity (11‑13) and protein 
phosphatase 2 enzymatic activity (14), inhibition of nuclear 
factor (NF)‑κB transcriptional activity (15), suppression of 
COX‑2 gene transcription (16), inhibition of IκB kinase‑β (17), 
increased hMLH1 expression (18), selection for DNA 
microsatellite stability (19), altering mammalian target of 
rapamycin signalling (20) and a direct allosteric activation 
of AMP kinase (21). More recently, the breakdown product 
of aspirin, salicylate, has been demonstrated to inhibit 
CREB‑binding protein/p300 acetyltransferase activity (22).
Therefore, it is reasonable to suggest that aspirin may 
act pleiotropically and there is some evidence that aspirin 
and other non‑steroidal anti‑inflammatory drug (NSAIDs) 
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may also affect the epidermal growth factor (EGF) receptor 
(EGFR) axis. For example, metabolites of the NSAID sulindac 
can inhibit EGFR signalling through the inhibition of EGFR 
phosphorylation and decreased EGFR expression in HT29 
colon cancer cells (23). A nitro‑derivative of aspirin was 
demonstrated to inhibit EGFR signalling in human ovarian 
cancer cells (24). Furthermore, in COX‑1‑positive ovarian 
cancer cells cultured in vitro, aspirin inhibited EGF‑associated 
protein kinase B (AKT) and extracellular signal‑regulated 
kinase (ERK) phosphorylation (25).
In an attempt to better understand the toxicity of aspirin to 
CRC cells, a number of aspirin‑like analogues were previously 
synthesised and diaspirins were identified as having the 
capacity to induce apoptosis in a CRC cell line (26), inhibit 
NF‑κB in vitro and cyclin D1 expression, and suppress tumour 
growth in vivo in a murine model of CRC without evidence of 
apparent toxicity to the animal (27). The aim of the present 
study was to investigate whether aspirin and analogues, 
including fumaryldiaspirin (F‑DiA), diflunisal and salicylates, 
which are common breakdown products of these compounds, 
are able to perturb EGF endocytosis in SW480 CRC cells (28), 
as these cells are known to express relatively high levels of 
wild type EGFR (29) compared with normal colonic epithelial 
primary cells, but exhibit decreased expression of COX‑1 and 
negligible levels of COX‑2 (30,31). Given the role of EGF 
signalling in tissue repair (32), the findings of the present study 
may improve our understanding of the molecular basis of the 
action of aspirin as a chemopreventive agent and its inhibitory 
effect on wound healing.
Materials and methods
Chemicals and reagents. Foetal bovine serum (FBS) was 
purchased from PAA Laboratories (GE Healthcare Life 
Sciences, Little Chalfont, UK) or Labtech International, Ltd. 
(Heathfield, UK). Precision Plus Protein Colour standards and 
nitrocellulose were obtained from Bio‑Rad Laboratories, Inc. 
(Hercules, CA, USA). Human recombinant EGF (PHG0313) 
was from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). 
Alexa Fluor 555‑EGF (E‑35350) was from Molecular Probes; 
Thermo Fisher Scientific, Inc. EGFR (D38B1) XP® rabbit 
antibody (Alexa Fluor 488‑conjugate; 1:100; cat. no. 5616) 
and EGFR rabbit antibody (D38B1; 1:100; cat. no. 4267) 
were from Cell Signaling Technology, Inc. (Danvers, MA, 
USA). Anti‑early endosome antigen 1 (EEA1) antibody 
(1G11) Early Endosome Marker (ab70521; 1:1,000) was from 
Abcam (Cambridge, UK). Anti‑GAPDH antibody (sc‑25778; 
1:1,000) was from Santa Cruz Biotechnology, Inc. (Dallas, 
TX, USA). VectaShield® mounting medium was from Vector 
Laboratories, Ltd. (Peterborough, UK). All other reagents 
were obtained from Sigma‑Aldrich; Merck KGaA (Darmstadt, 
Germany), unless stated otherwise. Aspirin analogues, 
detailed in Table I, were synthesised in‑house using previously 
described methods (26,27).
Cell culture. Colon cancer adenocarcinoma SW480 cells were 
obtained from the European Collection of Authenticated Cell 
Cultures (Salisbury, UK) and cultured in Leibovitz L‑15 medium 
(Thermo Fisher Scientific, Inc.) supplemented with 10% (v/v) 
FBS supplemented with L‑glutamine‑penicillin‑streptomycin 
(Sigma‑Aldrich; Merck KGaA). The OE33 and Flo‑1 
oesophageal cancer cell lines were a gift from Professor 
Tim Underwood (University of Southampton, Southampton, 
UK) and were cultured in Dulbecco's modified Eagle's 
medium high‑glucose with phenol red (Thermo Fisher 
Scientific, Inc.) containing 10% (v/v) FBS supplemented with 
L‑glutamine‑penicillin‑streptomycin (Sigma‑Aldrich; Merck 
KGaA). Cells were cultured in tissue culture flasks (Sarstedt, 
Inc., Newton, NC, USA) at 37˚C in a humidified incubator 
with 5% CO2, except for SW480 cells, which were cultured 
in the absence of CO2. Cells were regularly passaged at 
70‑80% confluence. The OE33 (also known as JROECL33) 
and Flo‑1 cells are commercially available oesophageal 
cancer cell lines (33). The OE33 cell line expresses COX‑2 and 
has been utilised to examine COX‑2 inhibitors with respect 
to proliferation (34). Both cell lines express EGFR (35). 
Additionally, the cell lines were investigated as they were 
derived from oesophageal carcinomas, and thus represent 
a counterpoint to a colorectal adenocarcinoma (SW480). 
Another aim of the present study was to elucidate whether 
the sensitivity to the salicylates observed in the SW480 cell 
line was specific to a cell line of CRC origin only, given 
the reported chemopreventative activity of aspirin against 
oesophageal cancer; reviewed in (36,37).
Cytotoxicity assay. Cell viability was assessed by MTT 
reduction assay (38) with modifications (39). Briefly, SW480 
cells were seeded at a density of 104 cell/well in a 96‑well 
plate and incubated overnight at 37˚C. Following 24 h, the 
culture medium was replaced with medium containing aspirin 
analogues (Table I) at 0.01, 0.03, 0.1, 0.3, 1 and 3 mM, and the 
cells were incubated at 37˚C for a further 48 h. A no‑treatment 
control was included in these experiments. Following 48 h of 
incubation, the medium was aspirated from each well, the cells 
were washed once with fresh medium to remove drugs, and 
300 µl MTT reagent (0.5 mg/ml) was added. The cells were 
incubated at 37˚C for 3 h and the solution was replaced with 
200 µl dimethyl sulphoxide (DMSO). The plates were incubated 
at 37˚C for a further 30 min and the conversion of MTT into 
formazan crystals was measured by recording changes in 
absorbance at 540 nm in a Multiskan Ascent microplate reader 
(Thermo Fisher Scientific, Inc.). The plates were protected 
from light throughout the procedure. Drug dosage ranged from 
0 to 3 mM. GraphPad Prism 7 (GraphPad Software, Inc., La 
Jolla, CA, USA) was used to plot dose‑response curves and to 
determine half maximal inhibitory concentration (IC50) values. 
All assays were performed in duplicates (n=3 experiments) and 
viable cells were expressed as the percentage relative to the 
negative control: Cell viability = [absorbance 540 nm (treated 
cells‑blank)/absorbance 540 nm (control cells‑blank)]x100.
Immunoblot analysis. Cells (5x104) were plated in 6‑well 
tissue culture plates and incubated overnight at 37˚C. Cells 
incubated with compounds (Table I) for the times stated 
were washed with ice‑cold PBS at 4˚C, gently scraped 
and suspended in 2X Laemmli sample buffer containing 
10% β‑mercaptoethanol (40) and 0.01% protease inhibitor 
cocktail (100X; 5871S; CST Biological Reagents Co., Ltd., 
Shanghai, China). The samples were then heated to 100˚C for 
20 min, centrifuged (18,000 x g; 5 min; room temperature), 
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analysed by discontinuous SDS‑PAGE with a 10% resolving 
gel and electro‑transferred using a Bio‑Rad Mini‑Trans 
Blot electrophoretic transfer cell (Bio‑Rad Laboratories, 
Inc.) according to the manufacturer's instructions onto 
polyvinylidene dif louride membranes (Immobilon®; 
IPVH00010; Merck KGaA). The membranes were incubated 
with blocking buffer [5% (w/v) bovine serum albumin (BSA) 
and 0.1% (v/v) Tween‑20 in TBS (TBST), or 5% non‑fat milk 
(w/v) and 0.1% (v/v) TBST, for GAPDH] for 1 h at room 
temperature, followed by incubation with the following 
specific antibodies: EGFR rabbit‑antibody (1:1,000), rabbit 
phosphorylated (p)EGFR Y1068 antibody (ab5644; 1:1,000; 
Abcam), rabbit pEGFR Y1045 antibody (2237S; 1:1,000; 
Cell Signaling Technology, Inc.), rabbit pEGFR Y1172 
antibody (ab135560; 1:2,000; Abcam) and GAPDH rabbit 
antibody in blocking buffer and incubated overnight at 4˚C. 
The membranes were washed extensively with TBST and 
incubated with horseradish peroxidase‑conjugated anti‑rabbit 
immunoglobulin (Ig)G (7074S; 1:2,000; Cell Signaling 
Technology, Inc.) for 3 h at room temperature. The membranes 
were then washed with TBST, prior to being visualised with 
Thermo Scientific™ Pierce™ ECL‑plus reagent (80196; 
Thermo Fisher Scientific, Inc.) according to the manufacturer's 
instructions, using CL‑Xposure™ X‑ray film (34088; Thermo 
Fisher Scientific, Inc.). ImageJ software v1.52 (National 
Institutes of Health, Bethesda, MD, USA) was employed for 
densitometric analysis of western blots. Band intensities were 
quantified (n=3 experiments) and pEGFR or EGFR levels were 
calculated relative to GAPDH, the loading control. pEGFR 
levels were also calculated relative to total EGFR. Data points 
represent mean ± standard error of the mean. Statistical 
analysis was performed using one‑way analysis of variance 
followed by Dunnett's post hoc test.
Microscopy. For EGF clustering, SW480 cells were seeded onto 
glass coverslips at ~0.3x106 cells/well and cultured in Leibovitz 
L‑15 medium containing 10% (v/v) FBS supplemented with 
antibiotics to 70‑80% confluence in 6‑well tissue culture 
plates. Cells were then cultured in serum‑free L‑15 medium 
with antibiotics for 48 h. Monolayers were cooled to 4˚C and 
incubated for 60 min in the presence of 100‑500 ng/ml Alexa 
Fluor 555‑EGF at 4˚C. For experiments testing compounds, 
serum‑starved cells were pre‑incubated at 37˚C for 30 min 
in the absence or presence of compounds (Table I), followed 
by 15 min at 4˚C prior to the addition of an equal volume of 
cold (4˚C) serum‑free culture medium containing 200 ng/ml 
Alexa Fluor 555‑EGF and incubation for 60 min allowing 
EGF binding. Prolonged incubation previously facilitated 
recruitment of ligand‑receptor complexes into clathrin‑coated 
pits (41,42). Cells were warmed to 37˚C over 25‑30 min to 
stimulate EGF and EGFR internalisation, washed with PBS, 
fixed for 5 min with cold acetone/methanol (‑20˚C; 1:1, v/v) 
and the coverslip was then placed onto a drop of VectaShield 
mounting medium prior to immediate epifluorescence or 
confocal microscopy at x400 magnification. For preliminary 
experiments, cells were incubated at 37˚C with 1 mM aspirin, 
Di‑A, F‑DiA or with 0.5 mM PN529 (Table I) for 30 min in 
serum‑free medium or with an equivalent final concentration 
of DMSO as described above, prior to the addition of 
fluorescently‑labelled EGF. Epifluorescence microscopy was 
carried out using an Olympus BX61 microscope with TXRED 
filter set (excitation, 580‑590 nm; emission, 615‑630 nm; 
Olympus Corporation, Tokyo, Japan). For confocal microscopy 
a Zeiss LSM510 Meta or a Zeiss LSM880 with Airyscan (Zeiss 
GmbH, Jena, Germany), equipped with an argon excitation 
laser (458, 488 and 514 nm), using a 63 x 1.4 NA oil immersion 
objective. DAPI (Dako; Agilent Technologies, Inc., Santa 
Clara, CA, USA) was used as a nuclear counter stain (room 
temperature, ≥30 min) in certain experiments
For EGFR clustering, SW480 cells were cultured on glass 
coverslips in 6‑well tissue culture plates to 70% confluence and 
serum‑starved for 48 h. For experiments testing compounds, 
cells were pre‑incubated at 37˚C for 30 min in the absence 
or presence of the drug, followed by 15 min at 4˚C prior to 
Table I. List of compounds.
Common name, synonym Chemical, formal name Laboratory number IC50 (mM) Source
Salicylic acid, SA 2‑hydroxybenzoic acid Not applicable 2.6 Commercially available
Aspirin, ortho‑aspirin 2‑acetoxybenzoic acid,  PN502 1.8 Commercially available
 acetylsalicylic acid
Diaspirin, DiA Bis‑carboxyphenylsuccinate PN508 0.8 (27)
Fumaryldiaspirin, F‑DiA Bis‑carboxyphenylfumarate PN517 0.2 (27)
Not applicable  m‑bromobenzoylsalicylic acid PN524 0.4 (27)
Not applicable Isopropyl m‑bromobenzoylsalicylate PN529 ND (27)
meta‑aspirin 3‑acetoxybenzoic acid PN548 3.8 Synthesised in this study
para‑aspirin 4‑acetoxybenzoic acid PN549 4.9 Synthesised in this study
Thioaspirin, ortho‑TASP 2‑acetylthiobenzoic acid PN590 0.2 Synthesised in this study
m‑thioaspirin, meta‑TASP 3‑acetylthiobenzoic acid PN591 0.5 Synthesised in this study
p‑thioaspirin, para‑TASP 4‑acetylthiobenzoic acid PN592 0.8 Synthesised in this study
Diflunisal, DIF 5‑(2,4‑difluorophenyl) salicylic acid Not applicable 0.08 Commercially available
IC50, half maximal inhibitory concentration; ND, not determined.
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the addition of equivalent volume of cold (4˚C) serum‑free 
culture medium containing 250 ng/ml (stock) recombinant 
(r)EGF (cat. no. E9644; Sigma‑Aldrich; Merck KGaA, 
Darmstadt, Germany) to achieve a final concentration of 125 
ng/ml rEGF. The cells were then incubated for 60 min at 4˚C 
to allow EGF binding. The cells were warmed to 37˚C over 
25 min to stimulate EGF clustering and EGFR internalisation, 
washed with PBS, fixed for 5 min with acetone/methanol 
(‑20˚C; 1:1, v/v) and incubated with blocking buffer for 
60 min at room temperature. The cells were then incubated 
with anti‑EGFR (D38B1) XP® rabbit antibodies (Alexa Fluor 
488‑conjugate; 1:100) for 60 min in blocking buffer at 37˚C, 
washed with PBST (0.02%) and the coverslips were placed 
onto a drop of Prolong Gold antifade reagent with DAPI 
mounting medium (cat no. P36935; Invitrogen; Thermo 
Fisher Scientific, Inc.) prior to fluorescence microscopy 
(x400). Aspirin, DiA, F‑DiA and PN529 were added at a final 
concentration of 0.5 or 1 mM to independent wells in 6‑well 
plates. The controls without aspirin analogue were fixed 
following EGF binding for 60 min (no EGF internalisation) 
or following warming of the cells for 25 min at 37˚C (with 
EGF internalisation).
For EEA1 staining, SW480 cells were seeded onto glass 
coverslips at ~0.3x106 cells/well and cultured to ~70% 
confluence in 6‑well tissue culture plates and serum‑starved for 
48 h. For experiments for preliminary testing of compounds, 
serum‑starved cells were preincubated at 37˚C for 30 min in 
the absence or presence of compounds, followed by 15 min 
at 4˚C, prior to addition of the equivalent volume of cold 
serum‑free culture medium containing 200 ng/ml Alexa Fluor 
555‑EGF (final concentration of 100 ng/ml) and incubation on 
ice for 1 h to allow EGF binding. In later experiments, the 
concentration was reduced to 20 ng/ml. Cells were warmed 
to 37˚C over 30 min to stimulate EGF internalisation, 
washed with cold (4˚C) PBS thrice and fixed for 5 min with 
acetone/methanol (1:1, v/v) at ‑20˚C on ice. Cells were washed 
with cold PBS and blocked in blocking buffer [3% (w/v) BSA 
and 0.2% (v/v) Tween‑20 in PBS] for 2 h at room temperature 
in the dark. Anti‑EEA1 antibody was added to cells at 1:1,000 
dilution and incubated at 4˚C overnight with gentle rocking. 
Cells were washed with cold (4˚C) blocking buffer [3% (w/v) 
BSA and 0.2% (v/v) Tween‑20 in PBS] thrice and incubated 
with goat anti‑mouse IgG H&L‑fluorescein isothiocyanate 
(ab6785; 1:1,000; Abcam) secondary antibody for 2 h at room 
temperature. Cells were then washed with cold blocking 
buffer [3% (w/v) BSA and 0.2% (v/v) Tween‑20 in PBS] thrice 
and with cold PBS prior to placing coverslips onto a drop of 
VectaShield mounting medium. Microscopy was performed 
using a Zeiss LSM 880 confocal microscope, equipped with 
405 and 561 nm excitation lasers using a 40x/1.30 NA oil 
immersion DIC M27 objective.
Image acquisition and processing. Images were acquired and 
processed with Olympus compatible software (IPLab Imaging 
software v3.1; BD Biosciences, San Jose, CA, USA) or Zeiss 
software [ZEN 2.3 lite (blue edition), or Zeiss LSM Image 
Examiner Version 3.2.0.115; both Carl Zeiss AG, Oberkochen, 
Germany] and minor brightness, contrast and tonal alterations 
were performed with Adobe Photoshop CS6 (Adobe Systems, 
Inc., San Jose, CA, USA) or GIMP (https://www.gimp.org/).
For semi‑quantitative determination of EGF internalisation, 
the goal of development of the proximity and density quotient 
(PDQ) was to establish a metric that provides a quantitative 
estimate of the degree of localisation of labelled EGF to the cell 
nucleus. A way of doing this would be to determine the mean 
density value of the protein molecules and another density 
value in the vicinity of the nuclei and calculate a quotient. A 
visual inspection of the data to be analysed demonstrated an 
effect, whereby the clustering around one nucleus would have 
a major effect on the overall density around a neighbouring 
nucleus. For this reason, it is necessary to count only those 
molecules, which are unambiguously within the influence of 
the nucleus being studied. This is achieved by defining the 
region of interest for each nucleus. Each molecule is allocated 
to a region defined by the closest nucleus. Within this region, 
the evenness of the distribution of proteins is measured by 
counting them within an area around each nucleus. The outer 
area is a torus extending from the full radius of the measure‑
ment area to half of that radius. The inner area is a disc within 
the torus. The PDQ for an individual nucleus is the ratio of the 
number of molecules counted in the outer area to those counted 
in the overall area. A larger PDQ indicates reduced clustering 
of molecules around the nucleus. Formally, the calculation 
of the PDQ is performed as follows: A set of nuclei, N, and 
a set of protein molecules, M were defined. A set of protein 
molecules associated with each nucleus, n, was identified as:
with dist(m,n) as the Cartesian distance of the molecule m 
from the centroid of the nucleus n.
Then, sets of molecules proximate to each nucleus were 
identified as:
with rad(n) as the mean radius of the nucleus and k as an 
empirical constant, selected to maximise discrimination of 
PDQ in the control sets.
The PDQ for a molecule is calculated as the ratio of the 
difference of the cardinalities of Pn and Qn and the cardinality 
of Pn.
The tools used to calculate the PDQ were CellProfiler (43) 
and the Python programming language (https://www.python.
org/). CellProfiler was used to identify, count and locate the 
two objects of interest, nuclei and protein molecules. The 
staining of the slides provided a clear contrast between the 
red‑rendered proteins and the blue‑rendered nuclei, thus 
the first operation was to split the image by colour channel. 
The nuclei required processing in order to be reliably and 
unambiguously identified, which included removal of objects 
<50 pixels across, smoothing and thresholding. Without the 
latter steps, the segmentation algorithm would split single 
nuclei into several objects. Identification of protein molecules 
required suppression of objects <3 pixels. It is to be expected 
that different slide processing would require tuning of the 
image processing in order to reliably identify the two types of 
objects. CellProfiler provided tables of data listing each of the 
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objects identified, its position and size. A Python program was 
written, which implemented the algorithm described above. It 
was used to further process these data. The value of k, which 
provided best differentiation between the positive and negative 
control sets, was 4.
Compound synthesis. Full details of all the compounds 
referred to in the present study are provided in Table I. Aspirin 
analogues were, wherever possible, synthesised as previously 
described (26,27). Meta‑apirin (PN548) and para‑aspirin 
(PN549) were made by a standard aspirin synthesis using 
3‑hydroxy and 4‑hydroxybenzoic acids as starting materials, in 
lieu of salicylic acid. The three isomeric thioaspirin analogues 
(PN590, PN591 and PN592, represented as ortho‑TASP, 
meta‑TASP and para‑TASP respectively) were prepared in 
good yields (~70%) from the corresponding mercaptobenzoic 
acids, by reaction with acetic anhydride in ice‑cold sodium 
hydroxide solution, as previously described (44). In the present 
study, sodium hydroxide, rather than the potassium salt, was 
used without observing any changes. While the previously 
published method (39) only describes the preparation of the 
meta‑ and para‑isomers (meta‑TASP and para‑TASP) it was 
demonstrated that the method also yields the ortho‑isomer 
(ortho‑TASP). The crude products in each case were 
demonstrated by thin layer chromatography and melting 
point comparison to be suitable for use without any further 
purification. Details of the additional compounds synthesised 
specifically for use in the present study are provided below. All 
percentage yields were comparable to the published values and 
within 15%. NMR spectra were recorded on a Jeol ECS‑400 
instrument.
Meta‑aspirin (3‑acetoxybenzoic acid): White powder; 
melting point (mpt), 131‑134˚C (literature, 131‑134˚C); 
13C‑NMR (CDCl3) δ=171.19, 169.32, 150.75, 130.88, 129.68, 
127.72, 127.33, 123.53, 21.14 ppm; Infra Red (IR), 3,400‑2,200, 
1,758, 1,675, 1,584 cm‑1.
Para‑aspirin (4‑acetoxybenzoic acid): White powder; mpt, 
183‑185˚C (literature, 187˚C; 190‑194˚C); 13C‑NMR (CDCl3) 
δ=171.31, 168.96, 155.06, 131.96, 126.88, 121.85, 21.25 ppm; 
IR 3500‑2200, 1754, 1677, 1602 cm‑1.
Thioaspirin (ortho‑TASP): White powder; mpt, 122‑125˚C 
(literature, 125.5‑126˚C) (45); 13C‑NMR (CDCl3) δ=193.27, 
171.48, 136.82, 132.88, 132.66, 131.92, 129.49, 129.40, 30.45 
ppm; IR 3,380‑1,960, 1,694, 1,676, 1,582, 1,565 cm‑1.
Meta‑thioaspirin (meta‑TASP): White powder; mpt, 
153‑156˚C (literature, 152‑153˚C) (44); 13C‑NMR (CDCl3) 
δ=193.29, 171.09, 139.85, 136.16, 131.19, 130.43, 129.46, 128.88, 
30.38 ppm; IR 3,380‑1,990, 1,685 (overlapping thioester and 
‑COOH C=O spectra), 1,583, 1,573 cm‑1.
Para‑thioaspirin (para‑TASP): White powder; mpt, 
200‑202˚C (literature, 202.5‑203.5˚C) (44); 13C‑NMR (CDCl3) 
δ=171.31, 168.96, 155.06, 131.96, 126.88, 121.85, 21.25 ppm; 
IR 3,380‑1,950, 1,683 (overlapping thioester and ‑COOH C=O 
spectra), 1,592, 1,566 cm‑1.
Results and Discussion
EGF and EGFR internalisation. EGFR is an ~170‑kDa 
transmembrane receptor tyrosine kinase, belonging to the 
ErbB family of signalling receptors, whose ligands include 
EGF and transforming growth factor‑α, with roles in cellular 
proliferation, survival and differentiation (46,47). Dysfunction 
in the EGFR axis as a consequence of receptor overexpression, 
amplification and/or mutation has been reported in colorectal, 
breast, brain, lung, pancreatic, oesophageal and head and 
neck neoplasias (48‑52). EGFR and NF‑κB signalling are 
intimately linked (53,54) and it has been reported that the 
aspirin analogues DiA and F‑DiA can perturb NF‑κB 
activity in SW480 cells and that salicylates can potentially 
antagonise wound healing. Therefore, the aim of the present 
study was to investigate the effect of aspirin and aspirin‑like 
molecules (26,27) on EGF endocytosis in the context of a rapid 
cell biological effect, in contrast to many experiments that 
examine the consequences of compound exposure of cells and 
tissues over protracted time frames (days). Compound toxicity 
was determined by the MTT assay and the IC50 values are 
presented in Table I. The aspirin analogues synthesised and 
tested contain modifications to either the number of rings, to 
the position of the acetyl group and/or have a substituted thiol 
group. Diflunisal is a difluorophenyl derivative of salicylic 
acid and is a clinically utilised NSAID with analgesic and 
anti‑inflammatory properties.
In preliminary experiments to assess compound 
effects on EGF internalisation, a commercially available 
fluorescence‑labelled, pH‑insensitive conjugate of EGF 
was used. Serum‑starved SW480 cells were incubated with 
aspirin analogues, cooled on ice to inhibit endocytosis and 
allowed EGF‑conjugate binding for 1 h prior to tracking the 
internalised EGF by confocal and DIC microscopy (Fig. 1) 
and immunofluorescence analysis (data not shown). In SW480 
cells incubated in the absence of compounds, following 
~25 min of warming to 37˚C, EGF was observed to internalise 
with clustering often in a perinuclear location, with the nucleus 
clearly visible (Fig. 1). However, in the presence of aspirin, 
DiA and F‑DiA, internalisation and perinuclear clustering was 
inhibited. In cells incubated with DiA, substantial clustering 
was noted to persist at or near the membrane, whereas with 
F‑DiA, staining was notably diffused. These data suggested 
that compounds based on salicylate may perturb EGF 
internalisation and affect signalling, given that correctly 
regulated EGF internalisation and signalling via endosomes 
are associated (55,56). To examine this phenomenon further, 
serum‑starved SW480 cells were incubated with compounds 
prior to stimulation with recombinant human EGF (125 ng/ml) 
and EGFR localisation was probed by immunofluorescence 
analysis using a commercially available anti‑EGFR monoclonal 
antibody. Peripheral, presumably membranous staining, was 
clearly visible in the absence of warming (Fig. 2A), indicating 
that the EGFR is robustly expressed in the SW480 cell line, 
as previously reported (29). Internalised punctate staining of 
the EGFR demonstrated close proximity to the nucleus when 
the cells were warmed to 37˚C within 25 min (Fig. 2B). In the 
presence of aspirin, DiA and F‑DiA, during the internalisation 
of the receptor, staining was substantially more diffuse with 
all compounds (Fig. 2C‑E). Furthermore, when cells were 
incubated with PN529 (isopropyl m‑bromobenzoylsalicylate), a 
toxic brominated salicylate (27), EGFR staining was markedly 
dissimilar compared with the control cells (Fig. 2B and F). 
Clustering of labelled EGFR to perinuclear locations was 
consistently observed following a 25‑min incubation in the 
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absence of compounds in cells warmed to 37˚C. However, in 
the presence of aspirin and, more prominently, in the presence 
of DiA, F‑DiA and isopropyl (m‑bromobenzoylsalicylate), 
discrete perinuclear clustering was substantially inhibited. 
These data suggest that aspirin and analogues rapidly perturb 
EGFR internalisation, and this observation may not solely 
be caused by a reduction in binding, as staining observed 
with fluorescence‑tagged EGF was robust even following 
aspirin, F‑DiA, PN524 or ortho‑TASP treatment (data not 
shown). Whilst the concentration of the tested compounds 
in the experiments may appear high in comparison with 
other chemotherapeutic agents, a range of 1‑5 mM or above 
is not uncommon in in vitro experiments investigating the 
molecular action of aspirin or salicylate (21,22,57,58), with 
levels of 0.5‑2 mM also reported as being physiologically or 
therapeutically relevant by a number of investigators (59‑62).
EGF endocytosis in the presence of salicylate derivatives. 
Ligand binding leads to conformational changes in EGFR 
and EGFR dimerization (63‑65), autophosphorylation of 
the cytoplasmic tyrosine kinase domain with subsequent 
downstream signalling through the RAS [mitogen‑activated 
protein kinase (MAPK)], phosphoinositide 3‑kinase (AKT) 
and janus kinase (JAK; signal transducer and activator of 
transcription factor 3) pathways (53,66,67). Concomitantly, the 
ligand receptor complex is internalised via clathrin‑dependent 
and ‑independent routes, depending on EGF levels, with 
clathrin‑mediated endocytosis prolonging signalling (68‑70). 
Signalling from endosomes with activated EGFR may 
persist (71,72) and the activated EGFR may ultimately be 
recycled or degraded (73). Indeed, internalised endosomes 
may be considered as signalling platforms (56). An early 
destination for internalisation is the EEA1‑positive endosomal 
compartment depending on whether or not a clathrin‑mediated 
endocytosis occurred (74). Clustering of late endosomes is 
Figure 1. Effects of aspirin, DiA and F‑DiA on EGF internalisation in SW480 
cells. Internalisation of Alexa Fluor 555‑EGF following 25 min at 37˚C 
examined by (A and B) confocal microscopy (left panel) and highlighting 
the clustering, with merged DIC image (right panel). Internalisation of Alexa 
Fluor 555‑EGF following 25 min at 37˚C following preincubation for 30 
min at 4˚C with (C) 1 mM aspirin, (D) 1 mM DiA or (E) 1 mM F‑DiA and 
stimulation by warming of the cells to 37˚C. *Indicates nuclei for the inter‑
pretation of DIC microscopy, arrowheads indicate tagged EGF and arrows 
highlight the plasma membrane. DiA, diaspirin; F‑DiA, fumaryldiaspirin; 
EGF, epidermal growth factor; DIC, differential interference contrast; IF, 
immunofluorescence.
Figure 2. Immunofluorescence analysis of the effects of aspirin and aspirin‑like 
analogues on EGFR internalisation in SW480 cells. Serum‑starved SW480 
cells were incubated with aspirin or diaspirin compounds and human EGF. 
The samples were warmed to stimulate EGF internalisation and stained 
using the EGFR XP® rabbit antibody (Alexa Fluor 488‑conjugate; green). 
(A) Vehicle control at 4˚C with cells incubated with 125 ng/ml EGF. Cells 
stimulated with 125 ng/ml EGF and warmed to 37˚C over 25 min with (B) no 
preincubation, (C) 1 mM aspirin, (D) 1 mM DiA, (E) 1 mM F‑DiA and 
(F) 1 mM isopropyl‑bromobenzoylsalicylate preincubation. Cells were fixed 
and observed by epifluorescence microscopy. Blue highlights DAPI‑stained 
DNA. Pronounced clustering of the EGFR to a perinuclear location occurs 
upon warming cells (arrowheads). In the presence of compounds, the clus‑
tering is less perinuclear and/or more diffuse (arrows). Magnification, x600. 
EGFR, epidermal growth factor receptor; EGF, epidermal growth factor; 
DiA, diaspirin; F‑DiA, fumaryldiaspirin.
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at a perinuclear location and mislocalised endosomes can 
compromise signalling quality (55). In addition, it has been 
suggested that EGFR can translocate to the nucleus and signal 
therein (75‑78).
EEA1 is a Rab5 effector, intimately involved in tethering, 
docking and fusion of early endosomes (79) and mediating 
crosstalk between signalling pathways (80). It was therefore 
examined whether spatial and temporal regulation of the 
internalisation of EGF was perturbed by examining the 
colocalisation of Alexa Fluor 555‑labelled EGF (100 ng/ml) and 
EEA1 following a chase in the absence and presence of aspirin 
and aspirin analogues. This was performed while additionally 
controlling pH alterations with HEPES (10 mM at pH 8; Fig. 3) 
or phosphate buffers (data not shown) to minimise acidification 
caused by the addition of the aspirin derivatives. Buffering 
did not appear to attenuate the effects exhibited by aspirin 
and aspirin analogues. Peripheral EGF staining, interpreted as 
membrane‑localised, was apparent without a chase, whereas 
EGF internalisation to a perinuclear location occurred in the 
absence of compounds upon warming to 37˚C in the vehicle 
control group (Fig. 3). In the presence of compound at 0.5 mM, a 
concentration used to reduce any non‑specific effects caused by 
acidification, and under buffered conditions, aspirin or aspirin 
analogues rapidly perturbed EGF internalisation (Fig. 3A). 
Colocalisation of EEA1 and EGF was consistently enhanced, 
as evidenced by dual staining, when cells were incubated with 
F‑DiA, suggesting that the pathway of internalisation of EGF 
in the presence of F‑DiA is substantially altered in comparison 
to aspirin and PN524, a brominated salicylate exhibiting an 
intermediate toxicity between aspirin and F‑DiA (27) to SW480 
cells. Furthermore, endosomal EEA1 staining was enhanced, 
when cells were incubated with F‑DiA, based on the intensity of 
the fluorescence in the perinuclear location.
EGF internalisation (at 100 ng/ml) was analysed 
semi‑quantitatively with PDQ measurements of the labelled 
EGF relative to the nucleus (Fig. 3B) in the presence of 
0.5 mM aspirin, PN517 (F‑DiA) or diflunisal. A larger PDQ 
indicated reduced clustering of molecules around the nucleus. 
Significant perturbation of internalisation was noted with all 
three compounds. It was previously demonstrated that F‑DiA 
is significantly more effective at inducing apoptosis in CRC 
cells compared with aspirin, strongly reduces cyclin D1 levels 
and inhibits NF‑κB activity in vitro (27).
Given that endocytosis of the EGFR has been proposed to 
occur via a number of pathways, depending on the saturability 
of EGF ligand‑induced receptor internalisation (42,81,82), the 
cells were additionally stimulated with relatively low EGF 
concentrations (20 ng/ml) under buffered conditions (HEPES). 
These experiments were performed to elucidate the influence 
of the tested compounds on EGF and EGFR internalisation and 
further utilised EEA1 staining (Fig. 4). Similar to experiments 
using 100 ng/ml EGF, aspirin and F‑DiA perturbed EGF 
internalisation compared with the vehicle control and 
colocalisation of EGF with EEA1 was markedly enhanced as 
a consequence of a brief incubation with 0.5 mM F‑DiA.
The universality of the phenomenon of perturbing EGF 
internalisation at 20 ng/ml was examined, with a wider range 
of salicylate derivatives (at 0.5 mM), including diflunisal. 
Dysregulation in EGF internalisation was noted with all 
compounds under HEPES‑buffered conditions (Fig. 5) 
Figure 3. (A) Effect of aspirin and aspirin analogues under HEPES‑buffered 
conditions on EGF internalisation (100 ng/ml) and EGF colocalisation 
with EEA1. Confocal analysis of SW480 colorectal cancer cells incubated 
with Alexa Fluor 555‑EGF and preincubated in the absence or presence of 
0.5 mM compound. Analysis was performed in the absence of compound 
with no warming and no EGF internalisation, and for cells stimulated with 
warming (37˚C) with and without indicated compounds. EGF fluorescence 
only (left panel). Merged image for EGF and stained for EEA1 (right panel). 
Images were acquired at 405 nm for DAPI nuclear stain (blue), 561 nm for 
Alexa Fluor 555‑EGF (red) and 488 nm for fluorescein isothiocyanate for 
EEA1 (green). Internalisation of EGF to a perinuclear location was noted 
upon warming to 37˚C (arrowheads). In the presence of compounds, inter‑
nalisation was perturbed, and with F‑DiA colocalisation of EGF with EEA1 
was observed (arrows). (B) Nuclear PDQ for labelled EGF was determined 
by image analysis of three repeated experiments; data points represent 
mean ± standard error of the mean. Statistical analysis comparing the PDQ of 
unstimulated and warmed cells without and with compounds was performed 
using Kruskal‑Wallis with Dunn's post‑hoc test. **P<0.01 and ***P<0.001. 
EGF, epidermal growth factor; EEA1, early endosome antigen 1; F‑DiA, 
fumaryldiaspirin; PDQ, proximity and density quotient; DIF, diflunisal.
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compared with the vehicle control, including salicylic acid 
per se (Fig. 5A), aspirins with modifications to the position of 
the acetyl group (Fig. 5B and F) and/or compounds with an 
additional thiol group (Fig. 5D, G and H). When internalisation 
occurred in the presence of compound, it was often more diffuse 
than normal and the outline of the cell membrane was visible 
in some instances, a phenomenon particularly pronounced 
when the cells were incubated with diflunisal (Fig. 5E). 
Images were analysed and the PDQ of the labelled EGF 
relative to the nucleus was determined (Fig. 5I). In summary 
the data strongly suggested that salicylates and derivatives, 
at modest concentrations, rapidly altered EGF internalisation 
Figure 4. Effect of aspirin analogues in HEPES‑buffered conditions on EGF 
(20 ng/ml) internalisation and EGF colocalisation with EEA1. Confocal anal‑
ysis of SW480 colorectal cancer cells incubated with Alexa Fluor 555‑EGF 
and preincubated in the absence or presence of 0.5 mM compound. Analysis 
was performed in the absence of compound with no warming and no EGF 
internalisation and for cells stimulated with warming (37˚C) with and 
without indicated compounds. EGF fluorescence only (left panel). Merged 
image for EGF and stained for EEA1 (right panel). Images were acquired at 
405 nm for DAPI nucleic stain (blue), 561 nm for Alexa Fluor 555‑EGF (red) 
and 488 nm for fluorescein isothiocyanate for EEA1 (green). Representative 
images were taken at x40 magnification in oil/1.30 NA. oil immersion objec‑
tive lens (n=3). Internalisation of EGF to a perinuclear location was noted 
upon warming (arrowheads). In the presence of compounds, internalisation 
was perturbed and with F‑DiA colocalisation of EGF with EEA1 was also 
observed (arrows). EGF, epidermal growth factor; EEA1, early endosome 
antigen 1; F‑DiA, fumaryldiaspirin.
Figure 5. Effect of salicylates and aspirin analogues on EGF inter‑
nalisation (20 ng/ml). Confocal analysis of SW480 colorectal cancer cells 
incubated with Alexa Fluor 555‑EGF and preincubated in the absence/
presence of 0.5 mM of the following compound under HEPES‑buffered 
conditions: (A) SA, (B) meta‑aspirin, (C) DiA, (D) meta‑TASP, (E) DIF, 
(F) para‑aspirin, (G) ortho‑TASP and (H) para‑TASP. Images were acquired 
at 405 nm for DAPI nucleic stain (blue) and 561 nm for Alexa Fluor‑EGF 
(red). Representative images were taken at x40 magnification, with an 
oil/1.30 NA oil immersion objective (n=3). Limited clustering of EGF to a 
perinuclear location occurred upon warming cells (arrowheads), but was 
absent with diflunisal. (I) Nuclear PDQ of labelled EGF was determined 
by image analysis of three repeated experiments; data points represent 
mean ± standard error of the mean. Statistical analysis comparing the PDQ 
of unstimulated and warmed cells with and without stated compounds was 
performed using Kruskal‑Wallis with Dunn's post‑hoc test. *P<0.05, **P<0.01 
and ***P<0.001 vs. EGF (warmed). EGF, epidermal growth factor; PDQ, prox‑
imity and density quotient. SA, salicylic acid; DiA, diaspirin; DIF, diflunisal; 
ortho‑TASP, ortho‑thioaspirin; meta‑TASP, meta‑thioaspirin; para‑TASP, 
para‑thioaspirin.
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and endocytosis. The titratability of the inhibition of EGF 
internalisation was tested for dose‑dependency in the 
SW480 cell line qualitatively with aspirin, F‑DiA (PN517) 
and diflunisal (selected because of clinical relevance and 
cytotoxicity) at concentrations below 0.5 mM (Fig. 6), and 
although observable with aspirin and F‑DiA, was most notably 
observed with diflunisal, thus arguing against a non‑specific 
phenomenon associated with the experimental design.
Aspirin and aspirin analogue effects on EGFR and EGFR 
phosphorylation. Non‑specific inhibition of kinase activity 
has been proposed as a mechanism of action for aspirin and 
sodium salicylate (59). Hence, compound effects on EGFR 
phosphorylation, focusing on cytoplasmic phosphotyrosine 
residues in the ligand‑induced autophosphorylation domain 
were examined, including Tyr1045, Tyr1068 and Tyr1173. 
Phosphorylated Tyr1045 acts a site for c‑Cbl interaction 
that results in receptor ubiquitylation and degradation of 
EGFR, and Cbl regulates receptor downregulation and 
signalling (83). Phosphorylation of Tyr1068 enhances binding 
of the growth factor receptor bound protein 2 (Grb2), which 
is necessary for entry into coated pits (41) and Ras/MAPK 
activation (84,85). Phospho‑Tyr1173 is involved in binding the 
tyrosine phosphatase SHP1 and signalling via recruitment of 
the adaptor proteins SHC and Grb2, resulting in control of 
the ERK activity (86‑88). In the present study, SW480 cells 
were incubated overnight with the compounds of interest and 
briefly stimulated with 200 ng/ml rEGF (5 min) in serum‑free 
medium. EGFR phosphorylation status was analysed by 
immunoblotting (Fig. 7A). The data suggested that inhibition 
of EGFR phosphorylation upon stimulation, by aspirin (ortho 
and meta) was weak. Tyr1045 and Tyr1173 phosphorylation was 
more sensitive to the presence of diaspirins, including F‑DiA 
(PN517) and PN524, and thioaspirins, including ortho‑TASP, 
meta‑TASP and para‑TASP, compared with Tyr1068. 
Thioaspirin (ortho‑TASP) was the sole compound able to 
inhibit phosphorylation at all sites tested herein. These findings 
suggested that aspirin and analogues at the concentration 
tested (0.5 mM), even when cells are stimulated with high 
rEGF concentrations (200 ng/ml), did not universally inhibit 
all autophosphorylation sites, which argues against aspirin or 
its analogues acting solely as a non‑specific kinase inhibitor, 
as suggested by Frantz et al (59). Due to the sensitivity of 
Tyr1045 to the compounds and its role in receptor degradation, 
the compound effects on EGF phosphorylation at this site with 
a 2‑h incubation period were further examined and modest 
changes were observed by immunoblot analysis (Fig. 7B). 
As aspirin was reported to normalise EGFR expression (89), 
the effect of aspirin and its analogues on total EGFR levels 
in SW480 cells was further investigated following a 24‑h 
incubation (Fig. 7C). SW480 EGFR levels were substantively 
affected by diflunisal, but weaker changes were observed as a 
result of incubation with F‑DiA (PN517), PN524 and PN529, 
with little evidence of a significant reduction in EGFR by 
aspirin or salicylate following a 24‑h incubation. pEGFR levels 
relative to total EGFR at pY1068 and pY1173 sites was totally 
inhibited by ortho‑TASP and significantly reduced at pY1045 
and pY1173 phosphorylation sites by meta‑TASP, para‑TASP, 
F‑DiA, DiA and PN524. The pEGFR level at pY1068, pY1045 
and pY1173 was increased by aspirin, meta‑aspirin and 
para‑aspirin (Fig. 7D).
Taken together, these data suggested that the EGFR axis 
was sensitive to aspirin and its derivatives. These compounds 
may have a rapid and profound impact on EGF endcoytosis 
and autophosphorylation (particularly ortho‑TASP with 
overnight incubation) and, furthermore, to a limited extent, 
EGFR expression, with the exception of diflunisal. Diflunisal 
markedly reduced EGFR expression and perturbed EGF 
internalisation, an observation that, to the best of our 
knowledge, has not been previously reported for a prescription 
Figure 6. Effect of selected aspirin analogues on EGF (100 ng/ml) internalisation in the SW480 cell line at concentrations <0.5 mM. Confocal analysis of 
SW480 colorectal cancer cells incubated with Alexa Fluor 555‑EGF and preincubated in the absence/presence of stated compound and vehicle control (0 mM) 
under HEPES‑buffered conditions. Images were acquired at 405 nm for DAPI nucleic stain (blue) and 561 nm for Alexa Fluor‑EGF (red). Representative 
images were captured at x400 magnification (n=3). EGF, epidermal growth factor; F‑DiA, fumaryldiaspirin; DIF, diflunisal.
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Figure 7. Effect of aspirin and analogues on pEGFR tyrosine kinase phosphorylation sites and EGFR. SW480 colorectal cancer cells were incubated with 
human rEGF (200 ng/ml) for 5 min following being treated with 0.5 mM compound (HEPES buffered) for (A) 24 h and probed with anti‑human EGFR 
pY1068, pY1045 and pY1173 antibodies accompanied by corresponding histograms, (B) 2 h and probed with anti‑human EGFR pY1045 and (C) 24 h and 
probed with an anti‑human EGFR (D38B1) XP rabbit antibody.
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drug used in the treatment of osteoarthritis and rheumatoid 
arthritis. Given that endocytosis of EGF is rapid with migration 
of the ligand‑receptor as a unit to a perinuclear location and 
then recycled being a canonical pathway for EGF (90) and the 
role of the proteasome in the processing and degradation of 
EGFR (91), it would be of interest to determine whether there 
is any association between diflunisal use and proteasomal 
degradation of EGFR.
Compound effects on EGF internalisation in Flo‑1 and 
OE33 oesophageal cancer cells. It was further explored 
whether the phenomenon reported herein was restricted to 
SW480 cells. To that end and due to evidence that aspirin is 
chemopreventive in oesophageal cancer (92,93), Alexa Fluor 
555‑EGF internalisation was examined in the presence of 
the stated compounds with HEPES buffering in Flo‑1 and 
OE33 oesophageal cancer cells. It was observed that aspirin 
and F‑DiA perturbed EGF internalisation (at 20 ng/ml) in the 
oesophageal cancer cell lines (Fig. 8). EGF internalisation 
was markedly affected by F‑DiA (PN517) in the Flo‑1 cells, 
whereas a modest effect was observed with aspirin.
The present study details a rapid and hitherto unreported 
effect of aspirin and analogues, which are likely to yield 
salicylates upon metabolism within cells and tissues, on EGF 
endocytosis. The study has relevance to wound healing, cellular 
proliferation and chemoprevention. It addressed the analyses 
at physiologically achievable levels (≤1 mM) of aspirin (60,61) 
and analogues, and examined EGF internalisation and 
EGFR phosphorylation with what is considered to be an 
experimentally legitimate concentration of EGF (20 ng/ml) 
under buffered conditions, as acidification of the cytosol may 
inhibit endocytosis.
Given the number of compounds tested and for the 
purposes of clarity the effect of compounds on EGF at unitary 
values of either 0.5 or 1 mM was investigated. It is recognised 
that these values are in certain cases >IC50 values for SW480 
cells reported herein but with the exception of diflunisal 
the fold‑differences are relatively modest; however, plasma 
concentrations of diflunisal range from 150‑350 µM (22). 
Most significantly, the concentrations employed for salicylate 
and aspirin tested were markedly <IC50 values and within a 
range (0.5‑2 mM) that has been reported to be physiologically 
relevant.
Although a substantial body of published work pertains 
to the effects of aspirin and NSAIDS on gene expression and 
apoptosis in cells of cancerous origin (26,27), experiments 
often focus on outcomes over hours/days. It was observed that 
ligand‑induced activation of receptor tyrosine kinases is rapid 
(within minutes); therefore, EGF endocytosis was investigated 
in the presence of aspirin/salicylates within time frames 
relevant to EGF signalling and endocytosis.
With respect to the findings presented herein, p38 
MAPK was proposed as a potential rapid target, based on 
previously published work. Cyclin D1 is overexpressed in 
cells with EGFR mutations (94). It has previously been 
reported that, in SW480 cells treated with F‑DiA, cyclin D1 
Figure 7. Continued. (D) Quantification of the effect of these compounds on pEGFR tyrosine kinase phosphorylation sites 1,068, 1,045 and 1,173 in relation to 
total EGFR expression. Cell lysates were analysed by SDS‑PAGE and immunoblotting. pEGFR and EGFR bands migrated at ~185 and ~180 kDa, respectively, 
molecular weight was estimated by interpolation using Precision Plus colour standards. Band intensities were quantified relative to GAPDH. C‑ represents 
unstimulated and untreated cells; C+ represents untreated cells stimulated with rEGF for 5 min. Data presented are the mean of three individual experi‑
ments ± standard error of the mean. *P<0.05, **P<0.01 and ***P<0.001 vs. C+ (one‑way analysis of variance followed by Dunnett's test). EGF, epidermal growth 
factor; EGFR, EGF receptor; pEGFR, phosphorylated EGFR; rEGF, recombinant EGF; Y, tyrosine; SA, salicylic acid; DIF, diflunisal.
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levels are significantly reduced and NF‑κB signalling is 
attenuated (27). It has previously been reported that cyclin D1 
is reduced in CRC cells treated with aspirin, a phenomenon 
which has been reported to occur in response to p38 MAPK 
activation within minutes (95). Furthermore, salicylate 
exposure to COS‑1 cells (58) can activate p38 MAPK also 
within minutes. A number of studies have implicated p38 
MAPK as regulator of endocytic trafficking (96,97) and 
EGFR internalisation (98). p38 MAPK can regulate mu 
opioid receptor endocytosis, with the early endosomal 
antigen EEA1 identified as a substrate for p38 MAPK, 
which impacts on Rab5 activity regulating endocytosis (99). 
It is suggested that the rapid dysregulation of endocytosis 
is caused by salicylates and aspirin rapidly activating p38 
MAPK and disrupting receptor trafficking, perturbing EGF 
signalling and ultimately controlling cyclin D1 levels. This 
may be facilitated by salicylate persisting/accumulating as a 
result of its long half‑life determined by pharmacokinetics 
analysis (100), and inhibition of NF‑κB and further known 
downstream targets. The relatively long half‑life of salicylate 
may be relevant to the chemopreventive nature of low‑dose 
aspirin: Accumulation in tissue reduces inf lammation 
and may further attenuate EGF signalling. These findings 
suggest that aspirin and salicylates may be useful in cancer 
treatment, where EGFR amplification, overexpression 
and constitutive activation in a cancer is notable, e.g., in 
glioblastoma (101).
With respect to the question of non‑salicylate NSAIDs also 
impacting on the EGFR signalling pathway, notwithstanding 
concerns regarding conflicting evidence regarding the 
efficacy of other NSAIDs (in comparison with aspirin) in 
reducing human cancer risk, e.g., in breast cancer (102), the 
evidence in the literature to date, as far as we are aware, 
other than work focused on sulindac affecting EGFR 
activation/inhibition, directly is limited. There are, however, 
reports of interrelationships between EGFR and PGE2: for 
example, activation of EGFR by EGF has been reported to 
stimulate PGE2 production (103).
Given the fundamental role of EGF signalling in cancer 
biology, the findings reported in the present study have 
relevance to the understanding of the chemopreventive activity 
of aspirin, particularly with respect to COX‑independent 
pharmacology. A schematic illustration of the effect of 
selected compounds on EGF internalisation is presented 
in Fig. 9, based upon the representation of the endosomal 
system by Taub et al (55). It is suggested that further 
research is required to evaluate the rapid effect of salicylates 
on the EGFR axis, with a focus on MAPK activation and 
EGF/EGFR trafficking and phosphorylation. Furthermore, 
experimentation on EGF signalling in normal tissues 
exposed to aspirin or diflunisal is required to establish the 
physiological relevance of the observations reported herein. 
An analysis of the response of other growth factors and their 
cognate ligands to physiological concentrations of salicylates, 
with a particular emphasis on growth factor trafficking and 
recycling, appears timely. From a biochemical perspective, 
salicylate is a lipophilic monohydroxybenzoic acid that can 
interact with lipid membranes (104,105). It is also conceivable 
that interference of salicylates with membrane structure may 
affect endocytosis (106).
Figure 8. Effect of aspirin analogues under HEPES‑buffered conditions on 
EGF (20 ng/ml) internalisation in Flo‑1 and OE33 oesophageal cell lines. 
Confocal analysis of oesophageal cancer cells incubated with (0.5 mM) or 
without compound and fluorescence‑conjugated EGF. (A) Negative control, 
without EGF internalisation in the absence of compound. Cells warmed to 
37˚C in (B) the absence of compound and the presence of (C) aspirin and 
(D) F‑DiA. Images were acquired at 405 nm for DAPI nucleic stain (blue) 
and at 561 nm for Alexa Fluor 555‑EGF (red). Representative images were 
recorded at x40 magnification using an oil/1.30 NA oil immersion objective 
lens. The close proximity of EGF towards the nucleus upon internalisation 
with warming is observed in Flo‑1 cells (arrowheads). In cells incubated with 
compound the EGF is less centrally located (arrows), particularly with F‑DiA 
in Flo‑1 cells. EGF, epidermal growth factor; F‑DiA, fumaryldiaspirin.
Figure 9. Schematic illustration of the effects of compounds on EGF inter‑
nalisation. EGF, epidermal growth factor.
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